Skip Navigation


Carcinogenesis Advance Access originally published online on June 5, 2009
Carcinogenesis 2009 30(8):1320-1329; doi:10.1093/carcin/bgp138
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
30/8/1320    most recent
bgp138v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Amantini, C.
Right arrow Articles by Santoni, G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amantini, C.
Right arrow Articles by Santoni, G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Triggering of transient receptor potential vanilloid type 1 (TRPV1) by capsaicin induces Fas/CD95-mediated apoptosis of urothelial cancer cells in an ATM-dependent manner

Consuelo Amantini1,*, Patrizia Ballarini2, Sara Caprodossi1, Massimo Nabissi1, Maria Beatrice Morelli1,3, Roberta Lucciarini1, Marco Andrea Cardarelli4, Gabriele Mammana5 and Giorgio Santoni1

1 Department of Experimental Medicine and Public Health
2 Department of Molecular, Cellular and Animal Biology, University of Camerino, via Madonna delle Carceri 9, 62032 Camerino (MC), Italy
3 Department of Experimental Medicine, University "La Sapienza", 00161 Rome, Italy
4 Pathology and Cytodiagnostic Unit
5 Urology Operative Unit, ASUR 9, 62100 Macerata, Italy

* To whom correspondence should be addressed. Tel: +39 0737 403319; Fax: +39 0737 403325; Email: giorgio.santoni{at}unicam.it

Herein, we provide evidence on the expression of transient receptor potential vanilloid type 1 (TRPV1) on human urothelial cancer (UC) cells and its involvement in the apoptosis induced by the selective agonist capsaicin (CPS). We analyzed TRPV1 messenger RNA and protein expression on human UC cell lines demonstrating its progressive decrease in high-grade UC cells. Treatment of RT4 cells with CPS induced cell cycle arrest in G0/G1 phase and apoptosis. These events were associated with rapid co-ordinated transcription of pro-apoptotic genes including Fas/CD95, Bcl-2 and caspase families and ataxia telangiectasia mutated (ATM)/CHK2/p53 DNA damage response pathway. CPS induced Fas/CD95 upregulation, but more importantly Fas/CD95 ligand independent, TRPV1-dependent death receptor clustering and triggering of both extrinsic and intrinsic mitochondrial-dependent pathways. Moreover, we observed that CPS activates ATM kinase that is involved in Ser15, Ser20 and Ser392 p53 phosphorylation as shown by the use of the specific inhibitor KU55933. Notably, ATM activation was also found to control upregulation of Fas/CD95 expression and its co-clustering with TRPV1 as well as RT4 cell growth and apoptosis. Altogether, we describe a novel connection between ATM DNA damage response pathway and Fas/CD95-mediated intrinsic and extrinsic apoptotic pathways triggered by TRPV1 stimulation on UC cells.

Abbreviations: Ab, antibody; ATM, ataxia telangiectasia mutated; CPS, capsaicin; CPZ, capsazepine; ER, endoplasmic reticulum; FACS, fluorescent activated cell sorting; FITC, fluorescein isothiocyanate; GAM, goat anti-mouse; HRP, horseradish peroxidase; JC-1, 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide; mAb, monoclonal antibody; mRNA, messenger RNA; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NHUC, normal human urothelial cells; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; RAG, rabbit anti-goat; RT, reverse transcription; SDS–PAGE, sodium dodecyl sulfate–polyacrylamide gel electrophoresis; TRPV1, transient receptor potential vanilloid type 1; UC, urothelial cancer

Received February 2, 2009; revised May 26, 2009; accepted May 28, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.